Daily close, T-120 (2/19/25) through T+5. Run-up high $18.15 on 5/30/25, low $12.82 on 4/16/25 (T-120 to T-1). FDA decision 8/6/25. Historical price action, not a forecast.
Positioning before the decision
On Jul 23, 2025, 14 days before the decision date, at-the-money options priced a move of ±9.0% through Aug 8, 2025 (the first listed expiry after the decision; ATM implied volatility 54%). The stock closed +1.9% at the first close across the decision and +5.7% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Decision facts
FDA decision date2025-08-06
DrugAJOVY (fremanezumab-vfrm)
IndicationEpisodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilogra
Was AJOVY (fremanezumab-vfrm) approved by the FDA?
Yes. The FDA approved the application for AJOVY (fremanezumab-vfrm) on August 6, 2025. The primary source is linked on this page.
What was AJOVY (fremanezumab-vfrm) under FDA review for?
The application covered Episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilogra. The FDA approved the application on August 6, 2025.
How did TEVA stock react to the FDA decision?
On the decision day TEVA moved +1.9%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.